Scotiabank raises BBB Foods stock price target on store expansion By Investing.com

Scotiabank raised its price target on BBB Foods (NYSE:TBBB) to $48 from $37, implying about 33% upside, but the article also highlights investor concerns after a fourth-quarter 2025 EPS miss of -$4.75 versus 0.16 expected. The company reported revenue of $21.97 billion and has a growth-driven store expansion model, with Scotiabank expecting about 33% Q1 fiscal 2026 revenue growth and more than 120 store openings. Despite the higher target, the stock is flagged as potentially overvalued and shares reportedly tumbled on the earnings disappointment.

Analysis

The key signal is not the street-high target itself, but the market’s refusal to reward a clean growth + store economics story after a recent earnings disappointment. That tells us investors are currently paying more attention to execution risk and capital intensity than to long-duration unit growth, which is usually what happens when the market starts discounting future margin compression before it has evidence of stabilization. For a name like TBBB, that creates a gap between operational momentum and equity multiple expansion that can persist for several quarters.

The second-order issue is that the logistics flywheel cuts both ways: every incremental store can improve coverage, but it also increases working-capital strain, labor complexity, and the probability that newer cohorts under-earn their cost of capital during rapid buildout. The market is likely underestimating how much of the next 12 months’ earnings power will still be diluted by immature stores, meaning headline revenue growth can stay strong while per-share economics disappoint. That makes the stock more sensitive to any slight deceleration in same-store sales or any hint that new unit productivity is flattening.

For SHOP, this is a sentiment-overhang read-through rather than a fundamentals shock. If investors are punishing a growth retailer on execution optics, they may also be less willing to pay up for other long-duration compounders until the market sees evidence that growth can reaccelerate without margin trade-offs. In that environment, the best-risked exposure is often relative value rather than outright longs in the same factor bucket.

The contrarian view is that the selloff may be setting up a better entry window if the next quarter confirms the store economics thesis. Because the market is already leaning negative, a modest beat on same-store sales or store openings could force a sharp re-rate as short-duration earnings fears get pushed out. The trade is therefore less about calling the business and more about timing the inflection in confidence; if that catalyst is not imminent, the multiple can stay compressed despite strong top-line delivery.

Key Decisions for Investors

• Avoid initiating fresh outright longs in TBBB until the next print; if long-term bullish, wait for post-earnings confirmation of same-store sales and new-store productivity. Risk/reward is better after evidence than before when the market is already pricing execution risk.
• Consider a tactical pair: long quality growth compounder SHOP vs short TBBB for 1-3 months if you expect the market to keep penalizing capital-intensive growth. The relative trade benefits if investors continue to prefer proven monetization over expansion stories.
• For event-driven accounts, buy TBBB downside-hedged exposure via call spreads only after a pullback and only into the next quarterly update. Best case is a 2-3x payoff if management proves margins are inflecting; worst case is limited premium loss if buildout remains dilutive.
• If already long TBBB, trim 25-33% into any relief rally and re-enter only on confirmation that mature-store mix is inflecting. This keeps exposure to the multi-year store expansion thesis while reducing downside from another execution miss.
• Watch for sector contagion in consumer/growth multiples over the next 2-4 weeks; if TBBB weakness spreads to other high-duration names, use that as an opportunity to short weaker balance-sheet growth stories rather than the highest-quality compounders.